openPR Logo
Press release

United States Pyelonephritis Treatment Market Projected to Expand at 5.8% CAGR, Reaching USD 1.68 Billion by 2033 | DataM Intelligence

10-09-2025 04:08 PM CET | Health & Medicine

Press release from: DataM intelligence 4 Market Research LLP

Pyelonephritis Treatment Market

Pyelonephritis Treatment Market

The global Pyelonephritis Treatment Market reached US$ 1,014.39 million in 2024 and is projected to reach US$ 1,682.83 billion by 2033, growing at a CAGR of 5.8% during the forecast period 2025-2033, according to DataM Intelligence.

United States: Recent Industry Developments

✅ In September 2025, The FDA approved a new extended-release antibiotic formulation for complicated urinary tract infections, including pyelonephritis.
✅ In August 2025, CDC updated treatment guidelines for antibiotic-resistant pyelonephritis cases, emphasizing targeted antimicrobial therapy.
✅ In July 2025, A major US healthcare system implemented rapid diagnostic protocols for pyelonephritis, reducing hospitalization times.

Japan: Recent Industry Developments

✅ In September 2025, Japan's National Center for Global Health launched a nationwide study on antibiotic resistance patterns in pyelonephritis cases.
✅ In August 2025, Japanese pharmaceutical company received approval for a novel combination therapy for multidrug-resistant pyelonephritis.
✅ In July 2025, Japanese researchers developed a rapid point-of-care test for early detection of complicated pyelonephritis cases.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/pyelonephritis-treatment-market?jd

Market Trends & Drivers

The Pyelonephritis Treatment Market is driven by increasing antibiotic resistance concerns and rising incidence of complicated urinary tract infections worldwide. Advancements in rapid diagnostic technologies and targeted antimicrobial therapies are revolutionizing treatment approaches. Growing healthcare awareness, improved diagnostic capabilities, and the development of novel antibiotic formulations are significantly accelerating market growth, particularly in emerging economies.

Competitive Landscape

The market features strong competition among pharmaceutical companies developing advanced pyelonephritis treatments.

Pfizer Inc. leads with broad-spectrum antibiotics and ongoing research in novel antimicrobial formulations.
Merck & Co., Inc. advances its portfolio with innovative antibiotic combinations and extended-release formulations.
GlaxoSmithKline plc focuses on developing targeted therapies for antibiotic-resistant infections.
Novartis AG invests in research for novel antibacterial agents and combination treatment strategies.
Johnson & Johnson provides comprehensive solutions including both pharmaceutical and diagnostic approaches.
Roche Holding AG develops advanced diagnostic tools and targeted treatment monitoring systems.
AstraZeneca PLC focuses on innovative antimicrobial therapies and prevention strategies.
Bristol-Myers Squibb Company explores novel mechanisms for combating drug-resistant infections.
Sanofi S.A. maintains a strong position in antibiotic development and combination therapies.
Daiichi Sankyo Company develops specialized treatments for complex urinary tract infections.

Segmentation

By Type (Acute Pyelonephritis, Chronic Pyelonephritis)
By Treatment Type (Antibiotics, NSAIDs)
By Route of Administration (Oral, Parenteral)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pyelonephritis-treatment-market?jd

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?jd

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us:

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:

DataM Intelligence is a full-service market research and consulting firm, guiding organizations from initial insight to strategic implementation. We transform proprietary data, emerging trends, and market developments into agile, actionable solutions.

Our robust methodology powers a vast research database featuring 6,300+ syndicated and custom reports across 40+ industries. We have delivered strategic solutions to 200+ companies in 50+ countries, addressing the core research challenges that drive growth for our clients.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release United States Pyelonephritis Treatment Market Projected to Expand at 5.8% CAGR, Reaching USD 1.68 Billion by 2033 | DataM Intelligence here

News-ID: 4216396 • Views:

More Releases from DataM intelligence 4 Market Research LLP

United States Hybrid Energy Storage Market Projected to Expand at 6.89% CAGR, Reaching USD 28.22 Billion by 2032 | DataM Intelligence
United States Hybrid Energy Storage Market Projected to Expand at 6.89% CAGR, Re …
The global Hybrid Energy Storage Market reached US$ 16.56 billion in 2024 and is projected to reach US$ 28.22 billion by 2032, growing at a CAGR of 6.89% during the forecast period 2025-2032, according to DataM Intelligence. United States: Recent Industry Developments ✅ In September 2025, Tesla launched its next-generation Megapack 2.0 with integrated lithium-ion and flow battery technology for grid-scale applications. ✅ In August 2025, The Department of Energy announced $2.1
United States Uterine Cancer Treatment Market to Reach USD 39.0 Billion by 2033, Driven by Rising Incidence and Advancements in Targeted Therapies | DataM Intelligence
United States Uterine Cancer Treatment Market to Reach USD 39.0 Billion by 2033, …
The global Uterine Cancer Treatment Market reached US$ 23,633.46 Million in 2024 and is projected to reach US$ 39,007.22 Million by 2033, growing at a CAGR of 5.4% during the forecast period 2025-2033, according to DataM Intelligence. United States: Recent Industry Developments ✅ In September 2025, The FDA granted breakthrough therapy designation for Novartis' new targeted combination therapy for advanced endometrial cancer following promising Phase III trial results. ✅ In August 2025,
United States Medical Device Contract Manufacturing Market 2025 | Growth Drivers, Key Players & Investment Opportunities
United States Medical Device Contract Manufacturing Market 2025 | Growth Drivers …
Market Size and Growth The global medical device contract manufacturing market size reached US$ 76.43 Billion in 2024 from US$ 69.54 Billion in 2023 and is expected to reach US$ 190.88 Billion by 2033, growing at a CAGR of 10.9% during the forecast period 2025-2033. Key Development: United States: Recent Industry Developments ✅ In August 2025, Flex Ltd. expanded its medical device outsourcing services for U.S. clients, focusing on design, prototyping, and full-scale manufacturing. ✅
United States Pulmonary Arterial Hypertension Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities
United States Pulmonary Arterial Hypertension Market 2025 | Growth Drivers, Tren …
Market Size and Growth The global Pulmonary arterial hypertension market size reached US$ 8.04 Billion in 2024 from US$ 7.59 Billion in 2023 and is expected to reach US$ 14.11 Billion by 2033, growing at a CAGR of 6.5% during the forecast period 2025-2033. Key Development: United States: Recent Industry Developments ✅ In June 2025, Merck announced that its Phase 3 HYPERION study of WINREVAIRTM (sotatercept-csrk) met the primary endpoint in recently diagnosed adults

All 5 Releases


More Releases for Pyelonephritis

Pyelonephritis Drug Market: Emerging Trends and Growth Forecast to 2033
The Pyelonephritis Drug Market is expected to reach approximately USD 2.36 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2033. Pyelonephritis Drug Market Overview The Pyelonephritis Drug Market is witnessing steady growth due to the rising prevalence of urinary tract infections and the growing need for effective treatment options to prevent kidney-related complications. Increasing antibiotic resistance has heightened demand for advanced therapies and novel
Pyelonephritis Drug Market Size, Share, Growth, Trends, Analysis and Forecast - …
The global pyelonephritis drug market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). A kidney infection, commonly known as pyelonephritis, is a form of urinary tract infection characterized by inflammation of one or both kidneys. Bacteria or a virus causes the illness, which usually starts in the urinary bladder and spreads to one or both kidneys. Confusion and back pain, chills and high fever, nausea
Healing the Kidneys: Global Pyelonephritis Drug Market 2024-2031
𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧: Pyelonephritis, a severe type of urinary tract infection (UTI) affecting the kidneys, can lead to complications if left untreated. The global market for pyelonephritis drugs plays a critical role in addressing this medical condition, offering treatment options to alleviate symptoms and prevent recurrent infections. As we delve into the dynamics of this market, examining its size, share, and the impact of COVID-19, we uncover a landscape shaped by innovation and
Pyelonephritis Market - Pipeline Review, H2 2022
HTF Market Intelligence released a new research report of 134 pages on title 'Pyelonephritis - Pipeline Review, H2 2022' with detailed analysis, forecast and strategies. The market Study is segmented by key a region that is accelerating the marketization. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources. This section also provides the scope of different
Pyelonephritis Treatment Market Size Estimated to Observe Significant Growth by …
A kidney infection, also known as pyelonephritis, is a type of urinary tract infection, wherein one or both kidneys are infected. The infection is caused by bacteria or a virus that commonly begins to infect urinary bladder and moves up to one or both the kidneys. Signs or symptoms of pyelonephritis can vary depending on age and could include confusion & back pain, chills & high fever, nausea & vomiting,
Pyelonephritis-Pipeline Review H2 2018
The Pyelonephritis Market which explains the future and present measurements of the market as for the patterns in play. The principle reason for the investigation is to legitimize the occurrences in the market by giving reader helpful and suitable bits of knowledge on the particulars of the market for the future extent of development and accessible prospects at the current situation with the market. The statistical surveying production additionally manages